Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S securities between November 2, 2022 and December 19, 2024 ...

Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.

We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best stocks to buy and ...

Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Novo Nordisk ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Novo Nordisk (NVO) has reportedly been criticized by a U.K. pharma industry group for mischaracterizing certain payments to ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...